Flight staff medical expertise with regard to several forms of myocardial disease

The article deals with features of the regularities characterizing different levels of organization of the animal body. The cell is not only an integrated but also indivisible organic integrity which is due to the interaction of the nucleus and cytoplasm determining all sides of its vital activity. From this viewpoint the results of experiments on transplantation of the embryo cell nucleus into an enucleated egg of amphibia and the data on somatic hybridization are estimated. All processes of the cell life, their growth, multiplication and differentiation develop within the tissue system and are determined by the regularities of its development. The integrated system of the organism of a multicellular animal unites all the forms of integration of multi-step systemic pattern at different organization levels. Among different categories the systems of tissues and their interaction within the organ are most integrated. The regularities of the tissue development can not be brough to the regularities of the development of the anatomical structure of organs. The integration of cell elements in a tissue system and intertissue relations is the basis of all forms of interdependence in the cell development and the organism structure.     

关于放射性发光涂料产品辐射防护标准的讨论

本文描述了我国放射性发光涂料的生产,使用状况和部分发光涂料产品的照射量测量结果。估算了全民剂量,并对放射性发光涂料的辐射防护标准进行了讨论。     

The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study

BACKGROUND: A three-arm Phase III randomized trial was performed to compare response rates, time to local or distant progression, and survival for patients with unresectable (Stage IIIA or IIIB) nonsmall cell lung carcinoma treated with standard fractionated thoracic radiotherapy (SFTRT) versus accelerated hyperfractionated thoracic radiotherapy (AHTRT) with or without combination etoposide and cisplatin chemotherapy. METHODS: This trial was initiated in 1992 by the North Central Cancer Treatment Group. Patients with Stage IIIA or IIIB nonsmall cell lung carcinoma were eligible. They were randomly assigned to either SFTRT (6000 centigray [cGy] in 30 fractions) or AHTRT (150 cGy twice daily to a total dose of 6000 cGy, with a 2-week break after the initial 3000 cGy); the AHTRT was given alone or with concomitant cisplatin (30 mg/m2, Days 1-3 and 28-30) and etoposide (100 mg/m2, Days 1-3 and 28-30). RESULTS: A total of 110 patients were entered on study. Eleven patients were declared ineligible or off study on the day of study entry. This analysis was confined to the 99 eligible patients. This article reports mature follow-up, because more than 80% of the patients have died. The median follow-up of living patients was 2.5 years. There were suggestions of improvement in the rates of freedom from local recurrence and survival for patients treated with AHTRT (with or without chemotherapy) as opposed to SFTRT (P = 0.06 and P = 0.10, respectively). The improvement in survival associated with AHTRT (with or without chemotherapy) was statistically significant for the subgroup of patients with nonsquamous cell carcinoma after adjustment for other potentially confounding factors (P = 0.02). No differences in freedom from systemic progression or survival were found in a comparison of AHTRT with chemotherapy and AHTRT without chemotherapy. CONCLUSIONS: These results suggest that treatment of Stage IIIA or IIIB nonsmall cell lung carcinoma with AHTRT with or without chemotherapy may improve freedom from local progression and survival as compared with SFTRT, especially for patients with nonsquamous cell carcinoma. The statistical powers to detect the observed differences in median time to local progression and survival were approximately 55% and 35%, respectively. Therefore, further investigation comparing SFTRT with AHTRT is warranted.